abstract |
The present invention provides an improved method of manufacturing Zabofloxacin D-aspartate. The present invention provides a novel method of manufacturing 8-methoxyimino-2,6-diaza-spiro[3,4]octane-2-carboxylic acid t-butyl ester succinate (TBDCS) or 2-(2,2,2-trifluoro-acetyl)-2,6-diaza-spiro[3,4]octan-8-one O-methyloxime methanesulfonate (TDMOS), which are separately the starting materials for manufacturing Zabofloxacin D-aspartate. The manufacturing method according to the present invention is suitable for mass production of Zabofloxacin D-aspartate for it enables manufacturing in high yield and high quality (HPLC purity ≥ 99.5%) as well as reducing the unit cost of production by using only 1.0~1.1 equivalents of TBDCS or TDMOS in a substitution reaction. |